How effective and safe are low molecular weight heparin (LMWH) and anticoagulants such as vitamin K antagonists (VKA) for the long term treatment of venous thromboembolism (VTE) in patients with cancer?
The authors were unable to include a number of possibly relevant studies because the required data were not available.While LMWH decreases the incidence of VTE, it might be more costly and less acceptable because of the subcutaneous route of administration.
The presence of cancer increases the risk of VTE four to six-fold.¹ Patients with cancer might also respond differently to anticoagulants compared with patients without cancer. LMWH is given by injection, whereas VKA is given orally. 1. Heit J A et al. Arch Intern Med 2000;160:809–815.